Thoughts and Acts of Aggression/Violence Toward Others Reported in Association with Varenicline
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: Thoughts and acts of aggression/violence toward others have been reported in postmarketing surveillance of varenicline, an aid to smoking cessation. Objective: To identify the common characteristics of these thoughts and acts of aggression/violence toward others and assess the likely relationship to varenicline treatment. Methods: We obtained 78 adverse event reports from the Food and Drug Administration MedWatch database containing medical terms describing possible acts or thoughts of aggression/violence; 4 additional cases were reported in clinical trials, and 3 others came from the published literature. We used psychiatric diagnostic criteria and an adverse event causality assessment tool to identify 26 case reports for study. Results: The selected cases described 10 events with assault, 9 cases of homicidal ideation, and 7 cases of other thoughts or acts of aggression/violence. The most frequent common characteristics were (1) inexplicable and unprovoked event, (2) the victim was anyone nearby, (3) no indication of a prior history of similar behavior in the patient, and (4) early onset of psychiatric adverse effects, often before stopping smoking. Where dechaltenge/rechalfenge information was available, psychiatric adverse effects resolved in 13/14 (93%) cases after discontinuation. Conclusions: The clear temporal relationship, lack of prior history of this behavior, and unusual nature of these events strengthens the accumulating scientific evidence that varenicline is associated with thoughts and acts of aggression/violence. We recommend that physicians and pharmacists ensure that all patients are informed of possible psychiatric symptoms of varenicline, including violent and aggressive thoughts. All patients should be advised to contact a heafth-care provider immediately if these symptoms occur and varenicline should be discontinued without delay.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Cited by
Singh, S., Loke, Y. K., Spangler, J. G., & Furberg, C. D. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.110218 · Cited by 286
Self-citationSuicidal Behavior and Depression in Smoking Cessation Treatments
Moore, T. J., Furberg, C. D., Glenmullen, J., Maltsberger, J. T., & Singh, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027016 · Cited by 150
Self-citationRüther, T., Bobes, J., De Hert, M., Svensson, T. H., Mann, K., Batra, A., Gorwood, P., & Möller, H. J. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2013.11.002 · Cited by 149
“Since varenicline was introduced to the market, there have been some reports of exacerbations of symptoms of existing psychiatric disorders during treatment [90,169,226,240] and some reports of psychiatric side effects in patients without a diagnosis of mental illness [202,203].”
BackgroundHarrison-Woolrych, M., & Ashton, J. (2011) · Drug Safety · doi:10.2165/11594450-000000000-00000 · Cited by 54
Yohn, N. L., Turner, J. R., & Blendy, J. A. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.211706 · Cited by 28
“Therefore this lack of anxiolytic activity during nicotine withdrawal may underlie the low success rate of varenicline in a subset of smokers (Garrison and Dugan, 2009; Moore et al., 2010).”
BackgroundEfficacy and safety of varenicline for smoking cessation in schizophrenia: a meta-analysis.
Ahmed, S., Virani, S., Kotapati, V. P., Bachu, R., Adnan, M., Khan, A. M., Zubair, A., Begum, G., Kumar, J., Qureshi, M., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00428 · Cited by 20
Metadata
- Authors
- Moore, T. J., Glenmullen, J., & Furberg, C. D.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2010-07-20
- Volume
- 44
- Issue
- 9
- Pages
- 1389-1394
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2168839982
- Cited by
- 31
- References
- 1
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.